GlassScriptPhysician profile
Megan A Louque
NPI 1447253794
$5,979.84
in general payments reported to CMS, 2019-2025
30 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 99% of Community Health/Public Health providers received nationally (typical 2025 total: $78.84).
See the full distribution for Community Health/Public Health
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $1,025 · 2023: $1,564 · 2024: $1,724 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,431.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $845.62 | 2021-2025 | Valtoco |
| Phathom Pharmaceuticals, INC. | $475.26 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $469.79 | 2021-2025 | Ozempic |
| Abbvie INC. | $397.82 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $366.50 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $293.31 | 2024 | Airsupra, Farxiga |
| Dexcom, INC. | $255.43 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbott Laboratories | $237.89 | 2022-2023 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $215.00 | 2023-2024 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $202.98 | 2022-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $200.43 | 2024-2025 | Xarelto, Spravato |
| Terumo Medical Corporation | $191.67 | 2021-2023 | Navicross, Glidewire, R2p Misago |
| Bayer Healthcare Pharmaceuticals INC. | $146.62 | 2022-2023 | |
| Janssen Biotech, INC. | $146.19 | 2025 | |
| Edwards Lifesciences Corporation | $141.55 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $118.37 | 2025 | |
| Ardelyx, INC. | $115.00 | 2024 | Ibsrela |
| Neurocrine Biosciences, INC. | $103.71 | 2025 | |
| Tris Pharma INC | $101.62 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $100.00 | 2023 | Quviviq |
| Lilly USA, LLC | $99.33 | 2024 | Zepbound |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.46 | 2024 | |
| Merck Sharp & Dohme LLC | $97.37 | 2023 | Verquvo |
| Cardiovascular Systems INC. | $96.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $95.58 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.34 | 2022 | |
| Genzyme Corporation | $77.24 | 2021 | |
| Inspire Medical Systems, INC. | $75.36 | 2025 | Inspire |
| Coloplast Corp | $72.84 | 2023 | Altis, Titan |
| Lundbeck LLC | $49.28 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Louque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.